The new device, which already gained CE mark approval, allows users to switch back and forth from one technique to the other as necessary. 

“It’s not just about scanning,” one specialist explained. “You need to have everything come together.”

The FDA-cleared device was built specifically with the tricuspid valve in mind. 

Pelacarsen, an investigational heart drug developed by Novartis, did successfully reduce Lp(a) levels in high-risk heart patients. However, it was unable to reduce the risk of major adverse cardiovascular events among those patients. 

A structured, nurse-coordinated, technology-enabled delivery model improved heart failure outcomes in routine care. 

Medtronic has received CE mark approval for a major change to the labeling of its Endurant stent graft system. A warning that the device has not been evaluated for the treatment of ruptured abdominal aortic aneurysms is no longer required.

The advanced algorithm, built to detect STEMI and STEMI-equivalent patterns in ECG results, gained the FDA's breakthrough device designation back in 2025.

The European Society of Cardiology announced that approximately 33,800 healthcare professionals from 170 countries participated in its latest annual conference. 

The newly cleared pVasc NET includes a dual-layer filter not available on the company's previous devices. 

The standard of care for hypertrophic cardiomyopathy has undergone a lot of change in recent years. Many more changes are likely on the way.

The study's authors reviewed data from more than 50,000 patients, confirming that patients given tirzepatide were less likely to die or experience a heart attack than those given an older diabetes medication.

A new review led by UCLA researchers examines the utility of commercially available AI tools for screening mammography and evidence surrounding their ability to detect interval cancers. 

The group was able to bill programs for COVID-19 tests and medical devices using artificial intelligence voices to justify claims submissions.